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Abstract  Medulloblastoma  encompasses  a  group  of 
aggressively  growing  cancers  that  arise  either  in  the 
cerebellum  or  brain  stem.  They  present  primarily  in 
children,  with  80–85  %  of  medulloblastomas  being  di-
agnosed  in patients of  16  years  and younger.  In adults, 
medulloblastomas are rare and account for less than 1 % 
of  intracranial malignancies.  Due  to  the  low  incidence 
of  medulloblastoma  in  adults,  the  biology  and  genet-
ics  of  adult  medulloblastomas  have  long  been  poorly 
understood.  Many  centers  therefore  still  treat  adults 
either  by  radiotherapy  only  or  by  using  glioblastoma 
protocols  (both  often  noncurative),  or  with  standard 
pediatric  medulloblastoma  regimes  (often  associated 
with dose-limiting toxicity).Current clinical staging sys-
tems  discriminate  between  standard-risk  or  high-risk 
patients  based  on  clinical  and  histological  parameters. 
However, clinico-pathological features often fail to accu-
rately predict  treatment  response.  In children, molecu-
larly  defined  risk  assessment has become  important  to 
improve  survival  of  high-risk  patients  and  to  decrease 
treatment-related  toxicity  and  long-term  sequelae  in 
standard-risk  patients.  However,  several  recent  studies 
have shown that adult and pediatric medulloblastomas 
are  genetically  distinct  and may  require  different  algo-
rithms  for  molecular  risk  stratification.  Moreover,  four 
subtypes of medulloblastoma have been  identified  that 
appear  at  different  frequencies  in  children  and  adults 
and  that  have  a  different  prognostic  impact  depending 
on  age.  Molecular  markers  such  as  chromosome  10q 
and chromosome 17 statuses can be used for molecular 
risk stratification of adult medulloblastoma, but only in 
a  subgroup-specific  context.  Here  we  present  an  over-
view of the current knowledge of  the genomics of adult 
medulloblastoma  and  how  these  tumors  differ  from 
their pediatric counterparts.






nancies  [1].  Due  to  the  infrequent  occurrence  of  this 
disease  in  adults,  not  much  was  known  until  recently 
about the biology and genetics of adult MB and there are 
no  prospective MB  trials  for  this  particular  age  group. 
Most centers therefore treat adults either by radiotherapy 
alone,  by  glioblastoma  protocols,  or  by  using  pediatric 
MB protocols, although it is well known that toxicity pro-
files  vary  greatly  between  children  and  adults,  leading 
to dose-limiting  toxicity  in a majority of adults  that are 
treated  on  pediatric  protocols  [2–4].  Medulloblastoma 
is not a single disease but in fact comprises a collection 





in β-catenin,  and  they have  an  excellent  outcome with 
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survival  rates  of > 90 %. Genomically  they  are  very  sta-
ble, except that almost all cases have lost an entire copy 
of chromosome 6. Interestingly, it is the adult cases that 
tend  to  lose only parts of  chromosome 6  [7]. Nearly all 
WNT MBs have classic histology. SHH MBs are characte-
rized by SHH signaling, caused by mutations in PTCH1, 
SMO,  or SUFU,  and/or  amplifications of GLI1  or GLI2, 
which all  lead to constitutive activation of the SHH sig-
naling pathway. Genomically  they  are  characterized by 
frequent loss of chromosome arm 9q, which harbors the 
PTCH1 gene. A subset of SHH tumors have amplified the 
MYCN  oncogene, which  in  this  subgroup  is  associated 
with a poor outcome [6, 8, 9].  In general  these patients 
have an intermediate outcome, although there are strong 






















and  references  therein).  In  adults,  the  SHH  subgroup 
forms  by  far  the  largest  subgroup,  accounting  for  57 % 
of all tumors. Other tumors in this age group are mainly 
characterized  as WNT  (13 %)  or Group  4  (28 %), while 
Group 3  tumors  are  very  rare  in  adults  (2 %)  [5,  6,  10].
Comparing survival rates for the four subgroups in adult 
patients versus those in pediatric patients showed some 
remarkable  differences.  In  particular,  Group  4  adult 









histology  is  rare  (6/175)  among  MBs  in  adults  [6].  All 
desmoplastic cases (31/175)  in adults were classified as 
SHH  tumors,  but  the opposite  is  not  true: Not  all  SHH 
tumors in adults are of desmoplastic histology (31/100). 
The majority are of classic histology (67/100), unlike the 
SHH  tumors  in  infants where  the majority display des-
moplastic  histology  (63/90).  Metastatic  disease  at  dia-
gnosis,  present  in  32 %  of  all  pediatric MB  patients,  is 
much less frequent in adult MB patients (7 %). Unlike in 
pediatric patients, where it is more frequently associated 





SHH medulloblastomas in adults
Interestingly, SHH MBs are the only subgroup that occur 
in a bimodal age distribution. They are frequent in infants 
and  adults  (both  57 %), whereas  they  are  quite  rare  in 
children (18 %) [6, 11, 12]. This unusual age distribution 
of  SHH  tumors  suggested  that  these  tumors  in  infants 
and  adults may not  be  the  same  and may  even have  a 







in  the  cerebellar  hemispheres while medulloblastomas 
in  children more  often  arise  in  the  vermis  and  the  4th 
ventricle [14]. Northcott et al. showed by expression pro-
filing and cytogenetic analyses  that pediatric and adult 
SHH  MBs  are  indeed  transcriptionally  and  genetically 
distinct  [12].  Most  notably, MYCN  amplifications  and 
chromosome  10q  deletions were  less  frequent  in  adult 
SHH  tumors  than  in  pediatric  SHH  tumors.  However, 
adult  SHH  MBs  harboring  10q  deletions  and/or  GLI2 
amplifications appeared to have a much worse prognosis 
as  compared  to  pediatric  SHH medulloblastomas  with 
the same genetic aberrations [12].
Molecular stratification
Current  treatment  decisions  for  medulloblastoma  are 
still  largely based on the clinical variables of metastatic 
disease at diagnosis and extent of surgical resection both 




















Fig. 1  Overall survival (OS) analyses of molecular and histological subgroups within adult medulloblastomas using Kaplan–Meier 
plots and log-rank tests. Tumor data are combined from gene expression studies and tissue microarray (TMA) analyses as de-
scribed in [6] plus 17 new adult cases that were recently added to our MB TMAs. a OS analysis of molecular subgroups among 
all adult medulloblastoma patients (n = 158). b OS analysis of classic, desmoplastic, and LCA histological subgroups among all 
adult medulloblastoma patients. c OS analysis of MYC or MYCN amplified adult medulloblastomas versus nonamplified adult 
medulloblastomas. d, g, j OS analyses of patients harboring 10q loss versus patients with a balanced 10q, either in all adult 
medulloblastoma patients (d), in SHH medulloblastomas only (g), or in Group 4 medulloblastomas only (j). e, h, k OS analyses of 
patients harboring 17p loss versus patients with a balanced 17p, either in all adult medulloblastoma patients (e), in SHH medul-
loblastomas only (h), or in Group 4 medulloblastomas only (k). f, i, l OS analyses of patients harboring 17q gain versus patients 
with a balanced 17q, either in all adult medulloblastoma patients (f), in SHH medulloblastomas only (I), or in Group 4 medullo-
blastomas only (l). Numbers on the Y axis indicate the fraction of surviving patients. Numbers on the X axis indicate the follow-up 
time in months. Numbers next to the Kaplan Meier plots indicate the total number of patients per subgroup and the number of 
events in that subgroup. NS not significant
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patients [7]. We therefore proposed a different algorithm 










(Fig.  1g–i).  For  Group  4  MBs,  all  adult  patients  tend 
to  have  a  poor  prognosis,  and  the  three  copy-number 
markers therefore do not show as significant a prognos-
tic  effect  as  they  do  for  SHH  tumors  (Fig.  1j–l).Conse-
quently,  the  DNA  copy  number  status  of  chromosome 
10 and 17 will be most useful as molecular markers  for 
risk stratification when combined with subgroup assess-
ment.  For  subgroup  assessment,  the  Nanostring  assay 
can be used, which predicts the tumor-specific subgroup 
with high accuracy, based on the expression level of 22 









The  recent  progress  that  has  been made  in  the  genetic 





ferent  frequencies and  they also  carry a different prog-
nostic significance when compared with  their pediatric 





medulloblastomas,  they  are  of  particular  interest  for 
molecularly  targeted  therapies, using  for  instance SMO 
inhibitors.  Initial  reports  treating  SHH  medulloblas-
tomas  in humans or mice were hopeful, but  the effects 
were  only  temporary  [19,  20].  Tumors  quickly  became 
resistant to these drugs either due to mutations in SMO 
or  to  amplification  of  downstream  signaling  members 
such  as MYCN, GLI1,  or GLI2  [21].  As  these  amplifica-
tions  are  already  present  in  some  primary  (untreated)







Table 1  verview of medulloblastoma molecular subgroup distribution, histological subgroup distribution, and metastatic 
groups in infants (age <4 years), children (age 4–16), and adults (age >16)
Infants Children Adults
Percentagea OSb Percentagea OSb Percentagea OSb
Molecular subgroups
WNT   1 NA 12 96 13 82
SHH 57 77 18 81 57 81
Group 3 34 29 26 55   2 25
Group 4   8 57 44 78 28 39
Histological subgroups Percentagea OSb Percentagea OSb Percentagea OSb
Classic 43 49 80 79 79 68
Desmoplastic 43 88   8 86 18 88
Large cell/Anaplastic 15 26 12 48   3 20
Metastatic stage Percentagea OSb Percentagea OSb Percentagea OSb
M0 68 66 68 81 93 71


























of  supratentorial  sites  (stPNET). Crit Rev Oncol Hematol. 
2009;71(2):165–79.
  3.  Padovani  L,  Sunyach  MP,  Perol  D,et  al.  Common  stra-
tegy  for  adult  and  pediatric  medulloblastoma:  a  multi-
center  series  of  253  adults.  Int  J  Radiat  Oncol  Biol  Phys. 
2007;68(2):433–40.
  4.  Spreafico  F,  Massimino  M,  Gandola  L,et  al.  Survival  of 
adults treated for medulloblastoma using paediatric proto-
cols. Eur J Cancer. 2005;41(9):1304–10.
  5.  Taylor MD,  Northcott  PA,  Korshunov  A,  et  al. Molecular 
subgroups  of  medulloblastoma:  the  current  consensus. 
Acta Neuropathol. 2012;123(4):465–72.
  6.  Kool M, Korshunov A, Remke M,et al. Molecular subgroups 
of  medulloblastoma:  an  international  meta-analysis  of 
transcriptome,  genetic  aberrations,  and  clinical  data  of 
WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta 
Neuropathol. 2012;123(4):473–84.




















13.  Grammel  D,  Warmuth-Metz  M,  von  Bueren  AO,et  al. 
Sonic hedgehog-associated medulloblastoma arising from 
the  cochlear  nuclei  of  the  brainstem.  Acta  Neuropathol. 
2012;123(4):601–14.
14.  Ang C, Hauerstock D, Guiot MC,et al. Characteristics and 
outcomes  of  medulloblastoma  in  adults.  Pediatr  Blood 
Cancer. 2008;51(5):603–7.
15.  Pfister S, Remke M, Benner A,et al. Outcome prediction in 






17.  Ellison  DW,  Dalton  J,  Kocak  M,et  al.  Medulloblastoma: 
Clinicopathological  correlates  of  SHH,  WNT,  and  non-











21.  Archer  TC,  Weeraratne  SD,  Pomeroy  SL.  Hedge-
hog-GLI  Pathway  in  Medulloblastoma.  J  Clin  Oncol. 
2012;30(17):2154–6.
